Abstract
Antiangiogenic chemotherapy is a common treatment option for patients with advanced ovarian cancer (OC) and has been proven to be effective and generally safe. Nevertheless, in rare cases, these drugs can give serious complications such as gastrointestinal perforations that can be even mortal or very difficult to treat and can heavily impact the clinical management. We present a rare case of bevacizumab-induced gastric perforation in a patient with advanced OC occurred during bevacizumab-including chemotherapy in an adjuvant setting. Surgical treatment was not possible due to the frailty of the clinical condition of the patient and the gastric perforation was successfully treated with endoscopic suturing.
References
1.
Miller
KD
, Siegel
RL
, Lin
CC
, Mariotto
AB
, Kramer
JL
, Rowland
JH
, et al Cancer treatment and survivorship statistics, 2016
. CA Cancer J Clin
. 2016
;66
(4
):271
–89
. 2.
La Rosa
VL
, Valenti
G
, Sapia
F
, Gullo
G
, Maria
A
, Rapisarda
A
. Psychological impact of gynecological diseases: the importance of a multidisciplinary approach
. Ital J Gynaecol Obstet
. 2018
;30
:23
–6
.3.
Wang
H
, Xu
T
, Zheng
L
, Li
G
. Angiogenesis inhibitors for the treatment of ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials
. Int J Gynecol Cancer
. 2018
;28
(5
):903
–14
. 4.
Burger
RA
, Brady
MF
, Bookman
MA
, Fleming
GF
, Monk
BJ
, Huang
H
, et al Incorporation of bevacizumab in the primary treatment of ovarian cancer
. N Engl J Med
. 2011
;365
(26
):2473
–83
. 5.
Perren
TJ
, Swart
AM
, Pfisterer
J
, Ledermann
JA
, Pujade-Lauraine
E
, Kristensen
G
, et al A phase 3 trial of bevacizumab in ovarian cancer
. N Engl J Med
. 2011
;365
(26
):2484
–96
. 6.
Saltz
LB
, Clarke
S
, Díaz-Rubio
E
, Scheithauer
W
, Figer
A
, Wong
R
, et al Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
. J Clin Oncol
. 2008
;26
(12
):2013
–9
. 7.
Wedam
SB
, Low
JA
, Yang
SX
, Chow
CK
, Choyke
P
, Danforth
D
, et al Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
. J Clin Oncol
. 2006
;24
(5
):769
–77
. 8.
Petrillo
M
, Nero
C
, Carbone
V
, Bruno
M
, Scambia
G
, Fagotti
A
. Systematic review of cytoreductive surgery and bevacizumab-containing chemotherapy in advanced ovarian cancer: focus on safety
. Ann Surg Oncol
. 2018
;25
(1
):247
–54
. 9.
Randall
LM
, Monk
BJ
. Bevacizumab toxicities and their management in ovarian cancer
. Gynecol Oncol
. 2010
;117
(3
):497
–504
. 10.
Hapani
S
, Chu
D
, Wu
S
. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
. Lancet Oncol
. 2009
;10
(6
):559
–68
. 11.
Qi
WX
, Shen
Z
, Tang
LN
, Yao
Y
. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups
. Eur J Clin Pharmacol
. 2014
;70
(8
):893
–906
. 12.
Han
ES
, Monk
BJ
. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
Gynecol Oncol
. 2007
;105
(1
):3
–6
. 13.
Hurwitz
H
, Fehrenbacher
L
, Novotny
W
, Cartwright
T
, Hainsworth
J
, Heim
W
, et al Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
. N Engl J Med
. 2004
;350
(23
):2335
–42
. 14.
Aghajanian
C
, Goff
B
, Nycum
LR
, Wang
YV
, Husain
A
, Blank
SV
. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
. Gynecol Oncol
. 2015
;139
(1
):10
–6
. 15.
Pujade-Lauraine
E
, Hilpert
F
, Weber
B
, Reuss
A
, Poveda
A
, Kristensen
G
, et al Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial
. J Clin Oncol
. 2014
;32
(13
):1302
–8
. 16.
Jain
RK
. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy
. Nat Med
. 2001
;7
(9
):987
–9
. 17.
Gordon
CR
, Rojavin
Y
, Patel
M
, Zins
JE
, Grana
G
, Kann
B
, et al A review on bevacizumab and surgical wound healing: an important warning to all surgeons
. Ann Plast Surg
. 2009
;62
(6
):707
–9
. 18.
Kamba
T
, McDonald
DM
. Mechanisms of adverse effects of anti-VEGF therapy for cancer
. Br J Cancer
. 2007
;96
(12
):1788
–95
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
